Atsena Therapeutics Receives FDA RPD Designation for X-Linked Retinoschisis Gene Therapy Candidate
On August 14, 2024, Atsena Therapeutics (New Haven, CT, USA), a gene therapy company focused on combating inherited blindness, announced…
New Horizons in Retinopathy of Prematurity Treatment, Tailoring Care for Premature Infants
Retinopathy of prematurity (ROP) is a prevalent complication in premature infants. The high incidence of cases1 leading to blindness or…
popular posts
latest posts
